<DOC>
	<DOCNO>NCT00535925</DOCNO>
	<brief_summary>The NID-2 study , multicentric study ( 21 centre enrol ) , plan two phase : Phase 1 ( observational study , complete 2007 ) : identification type-2 diabetic population typical DN , study rate renal cardiovascular event middle term follow-up . Phase 2 ( interventional study , start 2007 ) : randomization two group , group ( intervention group ) treat intensive multifactorial intervention whose aim reduce morbidity mortality due diabetic complication . The group ( control group ) continue conventional therapy . To avoid bias treatment center , randomization perform centre .</brief_summary>
	<brief_title>Nephropathy In Type 2 Diabetes Cardio-renal Events</brief_title>
	<detailed_description>The patient complete first phase NID-2 study ( observation ) enrol phase 2 study ( intervention ) .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Clofibric Acid</mesh_term>
	<criteria>type 2 diabetic patient AER &gt; 30 mg/die ( micro macroalbuminuric range ) least two determination last six month diabetic retinopathy patient follow outpatient clinic least 12 month type 1 diabetic patient &lt; 40 year old</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>nephropathy</keyword>
	<keyword>CV event</keyword>
</DOC>